Open AccessManagement of relapsed-refractory diffuse large B cell lymphoma
Author(s) -
Lalit Raut,
Prantar Chakrabarti
Publication year - 2014
Publication title -
south asian journal of cancer
Language(s) - English
Resource type - Journals
eISSN - 2278-4306
pISSN - 2278-330X
DOI - 10.4103/2278-330x.126531
Subject(s) - medicine , salvage therapy , rituximab , diffuse large b cell lymphoma , regimen , refractory (planetary science) , oncology , lymphoma , transplantation , surgery , chemotherapy , physics , astrobiology
Relapsed-Refractory Diffuse Large B Cell Lymphoma (RR DLBCL), which accounts for approximately one-third of patients with DLBCL, remains a major cause of morbidity and mortality. Managing RR DLBCL continues to be a challenge to the treating hemato-oncologist. Salvage high-dose chemotherapy followed by autologous stem cell transplantation is the standard of care for chemosensitive relapses in DLBCL. Various salvage regimens are available, but the quest for an optimal regimen continues. The addition of rituximab to the salvage regimen has improved the outcome of RR DLBCL. Several pertinent issues regarding the management of RR DLBCL are discussed in this short review.